Treated Relapsing Multiple Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Treated Relapsing Multiple Sclerosis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Treated Relapsing Multiple Sclerosis Today - Breaking & Trending Today

Teva Pharmaceutical Industries Limited: COPAXONE Label Now Indicates Its Use in Breastfeeding Mothers with Relapsing Multiple Sclerosis

Published: February 10, 2022

Change to COPAXONE(Glatiramer Acetate (GA)) Summary of Product Characteristics (SmPC) in breastfeeding is relevant for the Multiple Sclerosis ("MS") community and provides information for neurologists

Source: finanznachrichten.de

Related Topics:

United StatesNataliec EdwardsKerstin HellwigKatholisches Klinikum BochumDanilo LemboMedizinprodukte BfarGary SchneiderFiona CohenMariak HoutchensAmyl PhillipsNational German Multiple SclerosisDepartment Of NeurologyTeva Pharmaceuticals EuropeEuropean Academy Of NeurologyTeva PharmaceuticalsTeva Pharmaceutical Industries LtdTeva Pharmaceutical IndustriesGlatiramer AcetateProduct CharacteristicsMultiple SclerosisWorld EvidencePregnancy RegistryPrincipal InvestigatorTreated Relapsing Multiple SclerosisGerman Multiple Sclerosis

New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis

Published: October 13, 2021

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com

Related Topics:

United StatesTeva EuropeKerstin HellwigDanilo LemboKatholisches Klinikum BochumFiona CohenDepartment Of NeurologyTeva Pharmaceuticals EuropeTeva Pharmaceutical IndustriesRuhr University BochumTeva PharmaceuticalsTeva Pharmaceutical Industries LtdJosef HospitalPrincipal Study InvestigatorGerman Multiple SclerosisPregnancy RegistryTreated Relapsing Multiple SclerosisPharmaceutical IndustriesPrivate Securities Litigation Reform ActAnnual ReportTeva Pharmaceutical Industries LimitedBusiness WireCoronavirus PandemicMultiple Sclerosis